Non-infectious lung complications (NILC) are frequent, influencing morbidity and mortality of patients after allogeneic BMT. Although the term NILC encompasses a number of different entities, an association with GVHD has been noted for almost all of them. Our study was directed towards assessing the incidence and risk factors for developing NILC, as well as the response to treatment and long-term outcome. Forty (14.7%) out of 272 patients surviving for more than 3 months after allogeneic BMT, developed lung complications fulfilling the criteria for NILC. The evaluation was based on clinical investigation, radiologic imaging, lung function tests, broncho-alveolar lavage and biopsies. Risk factors were assessed by univariate and multiple statistical regression models, where chronic GVHD proved to be the only significant risk factor for the development of NILC (P = 0.011). In three patients NILC developed in direct association with donor lymphocyte infusions. The majority of patients responded well to treatment with corticosteroids and immunosuppressive drugs. NILC had no adverse effect on survival. The frequency of NILC was low in autologous (5%) as compared with allogeneic transplants (14.7%) but this difference was not statistically significant. Bone Marrow Transplantation (2000) 25, 1263-1268.
diffuse alveolar hemorrhage and lung fibrosis. [5] [6] [7] [8] [9] [10] [11] [12] The terms late-onset pulmonary syndrome or late-onset-noninfectious pulmonary complications have been used alternatively to describe those NILC occurring later than 3 or 6 months after BMT or PBSCT. 13, 14 The pathogenesis of NILC is unclear at present. The most controversial issue is the role of chronic GVHD. Chronic GVHD has been identified as a significant risk factor for bronchiolitis obliterans. 7, 14 In contrast, the role of chronic GVHD in the development of lymphocytic interstitial pneumonitis or bronchitis has not been settled. [15] [16] [17] [18] [19] In two recent series of 29 and 18 patients, chronic GVHD was identified as a potent risk factor for late-onset pulmonary syndromes. 13, 14 The authors assume that alloreactivity may be the underlying mechanism of lung disease in these cases.
The present data describe the results of a retrospective analysis of the frequency of NILC and their association with risk factors in 272 allogeneic transplanted patients with malignant and non-malignant hematologic diseases, surviving at least 3 months after BMT or PBSCT.
Materials and methods

Patients
A total of 272 consecutive patients with malignant and nonmalignant hematologic diseases who received an allogeneic stem cell transplant in our hospital between June 1989 and July 1997 and survived at least 3 months after transplantation were included in our retrospective analysis. Patient's disease status and transplantation characteristics are listed in Table 1 .
Conditioning therapy
Pretreatment for allogeneic transplantation most often included TBI (235 patients) plus chemotherapy. Twentyone patients received busulfan instead of TBI, either because they were receiving a second transplant (14 patients) or for logistic reasons.
TBI was performed at three different radiotherapy departments. Methods varied from anterioposterior/ AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myeloid leukemia; CsA = cyclosporin A; Mtx = methotrexate; TBI = total body irradiation; TLI = total lymphoid irradiation; Cy = cyclophosphamide; VP-16 = etoposide; CR = complete remission; CP = chronic phase. a Including non-Hodgkin's lymphoma (three patients), Hodgkin's lymphoma (one patient), paroxysmal nocturnal hemoglobinuria (one patient), Fanconi's anemia (one patient), multiple myeloma (six patients), myelodysplastic syndrome (16 patients).
posterioanterior set-ups to a lateral set-up. Radiation was delivered by linear accelerators. The vast majority of patients received 6 ϫ 2 Gy over 3 days (12 Gy), a minority 10 ϫ 1.4 Gy (14.4 Gy) for 4 days. The dose rates were administered at 14 cGy/min and 20 cGy/min, respectively. Preparative drugs included cyclophosphamide 2 ϫ 60 mg/kg, etoposide 60 mg/kg, or a combination of both. After 1996, thiotepa 10 mg/kg was frequently added to cyclophosphamide. Other drugs used for conditioning are listed in Table 1 .
Eight out of 16 patients with aplastic anemia were treated with 4 ϫ 50 mg/kg cyclophosphamide and total lymph node irradiation with 7.5 Gy. The other eight patients received only cyclophosphamide and anti-thymocyte globuline (ATG).
Type of transplant and GVHD prophylaxis
Two hundred and thirty-three patients received allogeneic bone marrow transplants (BMT) and 39 allogeneic peripheral blood stem cell transplants (PBSCT). Cyclosporin A (CsA) and methotrexate (Mtx) were used as GVHD prophylaxis in 50% of patients; in a minority methotrexate was replaced by steroids or steroids were added to the combination of CsA/Mtx (Table 1) . Twenty-eight percent of patients received T cell-depleted allogeneic stem cell transplants, with the bone marrow either depleted by Campath1M 20 or peripheral blood stem cells depleted by CD34 selection (Ceprate SC; Cell Pro, Bothell, WA, USA) plus either CD2 depletion (Ceprate SC) or CD3 depletion (Variamax, Miltenyi, Bergisch-Gladbach, Germany).
In order to estimate the influence of alloreactivity on the development of NILC, we used a control group of autologous and syngeneic transplanted patients (26 patients in total), who received total body irradiation and chemotherapy doses comparable to allogeneic transplantation.
In these patients, treatment of multiple myeloma (10 patients), non-Hodgkin's lymphoma of low malignancy (five patients), chronic myeloid leukemia (four patients), acute lymphoblastic leukemia (three patients) and acute myeloid leukemia (four patients) included irradiation with either 8.5 to 9 (nine patients) or 12 Gy (17 patients) total body doses and high-dose chemotherapy. Autologous grafts were acquired from bone marrow (three patients) and peripheral blood stem cells (23 patients).
Inclusion criteria and definition of NILC
Patients presenting with clinical symptoms, abnormal chest X-rays and/or abnormalities in pulmonary function were included in the evaluation. Broncho-alveolar lavage was performed in 33 patients to exclude infection, otherwise blood, urine or sputum cultures were evaluated. Histology was obtained by transbronchial or open lung biopsy. Standard culture and staining methods for bacterial, viral and protozoan pathogens were employed. Patients with adult respiratory distress syndrome associated with septicemia or multi-organ failure were excluded, as well as all patients, who did not survive the first 3 months.
The generic term NILC was used to describe both welldefined entities such as idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, bronchiolitis obliterans and lung fibrosis as well as patients with poorly defined syndromes which we have called pneumonitis.
Statistical methods
Besides descriptive statistical methods, data were analyzed with SAS software. 21 Univariate tests (chi square, Fisher's exact) were employed to identify possible risk factors for the development of NILC as proportional variables without adjustment. In order to exclude confounding variables, a multivariate logistic regression analysis was performed. 22 The following variables were included in covariate analysis: acute and chronic GVHD, age, sex, matched unrelated donor transplantation, mismatch transplantation, GVHD prophylaxis with CsA/Mtx, T cell depletion, second transplantation and conditioning with busulfan instead of TBI.
No reliable data could be collected concerning smoking history and exposition to other toxic agents before transplantation and were therefore not considered. The log-rank test was used to assess differences between the groups of patients with and without NILC in Kaplan-Meier estimates of survival.
Results
Frequency, symptoms and time of appearance of NILC
Lung disease without identification of an infectious etiology developed in 40 out of 272 (14.7%) patients surviving for more than 3 months after either allogeneic BMT or PBSCT. Table 1 shows the diagnoses and characteristics of patients with NILC.
The clinical symptoms described by the patients are listed in Table 2 . Only two patients were asymptomatic and were identified by pathologic lung function tests and radiologic abnormalities.
NILC occurred between 1 and 36 months after transplantation. The majority (82.5%) of cases were diagnosed between 3 and 12 months. In one of three patients developing NILC before 3 months after transplantation, diffuse alveolar hemorrhage was identified. Lung fibrosis was diagnosed in two of four patients with late occurring NILC (Ͼ12 months).
Diagnostic procedures and diagnoses of lung diseases
In 32 of 40 patients with NILC, chest X-rays showed either interstitial or alveolar infiltrates. Computer tomographic (CT) imaging was performed in 20 of these patients showing either ground glass opacities, interstitial fibrosis or alveolar infiltrates. Eight patients showed no pathologic results in radiologic imaging.
Lung function tests were performed before BMT and patients with highly pathologic results were excluded from transplantation. Lung function tests (Table 3) detected minor to severe hypoxemia in all NILC patients. Thirtythree percent showed severe restrictive lung function changes (vital capacity Ͻ60% of expected values). Obstructive lung function patterns were observed in 45% of these patients (Ͻ70% FEV1/FVC). The diffusion capacity for carbon monoxide (DLCO) was evaluable in 23 of 40 NILC patients and was moderately or severely reduced in 47% (adjusted in case of anemia). Broncho- alveolar lavage (BAL) was performed in 33 patients without major complications.
In most patients differential cell counts in BAL were dominated by monocytes. Lymphocytosis, defined as more than 25% lymphocytes in differential cytology, was found in nine of 33 patients. The phenotype of T lymphocytes was determined when lymphocytosis occurred and in five of these cases, CD8-expressing cells predominated.
Histological specimens were obtained in 22 of 40 patients with NILC by transbronchial biopsy and in five by additional open lung biopsy. The pathological diagnoses ranged from desquamative pneumonia (three patients), lymphocytic (five patients) and unspecific inflammation (seven patients) to mild (five patients) or severe fibrosis (two patients). In six of the 18 patients without histopathological evaluation a clinical diagnosis was established. We identified one patient with diffuse alveolar haemorrhage, three with bronchiolitis obliterans and two with lung fibrosis. Thus we were able to assign a diagnosis to 28 out of 40 patients (70%) with NILC.
Assessment of risk factors
Logistic regression analysis was performed to investigate the influence of age, sex, mismatched or matched unrelated transplantation, GVHD prophylaxis, acute GVHD, chronic GVHD, busulfan and second transplants on the development of NILC (Table 4) .
A clinical diagnosis of chronic GVHD was established in 107 (39%) of 272 patients surviving for longer than 3 months, and in 24 of 40 (60%) patients with NILC. Signs of GVHD (skin, gut, liver) developed either simultaneously with (11 patients) or before (eight patients) the manifestation of lung disease, while in eight of the 27 patients, NILC developed before chronic GVHD became manifest. Therefore, only those 19 patients were included in logistic regression analysis for the variable chronic GVHD, where pneumonitis developed later than 3 months after transplantation and evidence of chronic GVHD was found in other organ systems. Univariate and multiple statistical analysis revealed that chronic GVHD was the only significant risk factor for NILC (P = 0.011). There was a trend for a higher Bone Marrow Transplantation Table 4 Results of multivariate analysis for assessment of risk factors for development of non-infectious lung complications (NILC) frequency of NILC in patients treated with second transplantations (univariate analysis P = 0.0312 chi square, multiple logistic regression P = 0.11, odds ratio 3.63). Neither the conditioning regimen, acute GVHD, the type of GVHD prophylaxis, the degree of histocompatibility, nor the type of TBI regimen showed any statistical association with the incidence of NILC. In order to assess the relevance of alloreactivity, we compared the study group with a control group of 26 patients who received an autologous or syngeneic bone marrow transplant after conditioning with TBI/chemotherapy in doses equivalent to those used for the allogeneic recipients. The incidence of NILC was very low in the control group. Only one of these patients developed a NILC which was interpreted as toxic pneumonitis. Although NILC were rare in autologous and syngeneic in comparison to allogeneic (40 with NILC out of 272) transplanted patients, the difference was not statistically significant due to the small sample size and low number of events in the control group.
Association of NILC with donor lymphocyte infusions
Forty-one patients received donor lymphocyte infusions (DLI) during the period investigated, either prophylactically or for the treatment of relapse of malignant disease. Lung diseases fulfilling the criteria for NILC developed between 2 and 3 months after DLI in three patients simultaneously with or after the appearance of other signs of GVHD. An association with the conditioning therapy for BMT seemed unlikely, because DLI were given between 6 and 18 months after BMT. No other possible predisposing factor could be detected, therefore we suggest that the development of NILC in these patients was caused by the infusion of alloreactive T cells.
Therapy of NILC and response to therapy
Thirty-eight patients were treated with prednisolone at a dose of 1-2 mg/kg, 23 patients were treated with additional immunosuppressive drugs (usually CsA). Two patients were not treated because they showed spontaneous resolution of their pathological lung function tests.
Thirty-six (90%) of 40 patients responded to immunosuppressive treatment, in 28 patients (70%) the response was durable. In eight patients a relapse of lung disease was seen after the tapering of steroids and they responded to a second course of treatment. Four patients were refractory to treatment (one patient with severe fibrosis, one with bronchiolitis, two with pneumonitis) and died of progressive NILC.
We observed a high incidence of infections, especially pulmonary infections, in patients treated for NILC with immunosuppressive drugs. Five patients developed bacterial pneumonias, one cytomegalovirus -IP, another Varicella -IP, one aspergillus pneumonia and one septicemia. In addition, we observed one case of cerebral toxoplasmosis and two patients suffered from recurrent bacterial bronchtis. Four patients died due to infections (one Varicella -IP, one aspergillus pneumonia, one pneumonia of unknown origin, one septicemia). Three further patients died due to causes unrelated to NILC and its treatment. Two patients suffered relapses of their original malignancy and one patient died of a secondary tumor. Thus, the overall mortality in the group with NILC was 11/40 (27.5%). Surprisingly, the presence of NILC appeared to have no negative impact on survival. In fact, when analyzed by the KaplanMeier method, there was a trend for better survival in patients with NILC compared to the group of patients without NILC (P = 0.06 by log-rank test) (Figure 1 ). This difference was not due to a lower relapse rate in the NILC group and remains unexplained.
Discussion
This paper describes the results of a large single center study on the incidence, pathogenesis and outcome of patients with noninfectious lung complications after allogeneic stem cell transplantation. The main findings of the study can be summarized as follows: NILC are frequent complications of allogeneic stem cell transplantation, the In our series of patients we oberved an incidence of NILC of 14.7%. This is very similar to the incidence of 10% and 20% described in two large recently published series. 13, 14 This degree of agreement between these studies is somewhat surprising given that the term non-infectious lung disease is a diagnosis of exclusion. Our study cannot provide reliable data concerning the incidence of the various entities subsummed under the term NILC, because histopathological information was only available for slightly more than half the patients and was not diagnostic in a significant proportion of patients. This is also true for the two other published series cited above, therefore there is a need for more refined diagnostic methods.
Our conclusion that NILC are a manifestation of chronic GVHD in the majority of patients is based on the following pieces of evidence: Firstly, there is a clear-cut statistical association between the presence of chronic GVHD and the risk of developing NILC; in fact, in multivariate analysis chronic GVHD was the only relevant risk factor. Secondly, there was a large difference in the incidence of NILC between patients receiving autologous and patients receiving an allogeneic stem cell transplant. Finally, we observed the development of NILC in direct association to treatment with DLI.
This statistical association of chronic GVHD with NILC has been described by several authors. 13, 14, 19, 23 There is, however, considerable controversy with respect to its association with the various entities summarized under the term NILC. Whereas most authors seem to agree about the important role of chronic GVHD in the pathogenesis of bronchiolitis obliterans and lymphocytic interstitial pneumonitis, [7] [8] [9] 15, [24] [25] [26] the relationship between chronic GVHD and lymphocytic bronchitis remains unclear. 17, 18 From a pathophysiological point of view the very low incidence of NILC in the group of patients receiving autologous stem cells provides convincing indirect evidence for the involvement of alloreactive T cells in the pathogenesis of NILC. Only one patient out of 25 (4%) autologous patients developed a NILC compared with 40 out of 272 allogeneic patients (14.7%). Unfortunately our study had insufficient statistical power to demonstrate that this difference is significant.
The most direct evidence for the involvement of alloreactive T cell in the pathogenesis of NILC is provided by our experience with the infusion of donor lymphocytes 6 to 18 months after the original transplantation. Three out of 41 patients treated with DLI developed NILC in association with symptoms of extensive chronic GVHD in typical target organs. To our knowledge, this is the first time that the induction of NILC by DLI has been described. It is unlikely that other causes were responsible for the development of NILC given that the donor lymphocytes were given 6 to 18 months post transplant, there was no evidence of lung disease prior to DLI and the patients were not taking any drugs known to cause lung damage.
Our hypothesis that alloreactive T cells are responsible for a significant number of cases of NILC is also supported Bone Marrow Transplantation by experimental evidence. Cooke et al 27 have demonstrated that in a murine model of human HLA-identical sibling BMT, donor T cells can cause an idiopathic pneumonia syndrome similar to NILC. Analyses of lymphocytes in lung tissue and alveolar lavage fluid of patients with pneumonitis after BMT have also provided evidence that lung damage in many of these patients is caused by a local immune response [28] [29] [30] and CD8ϩ T lymphocytes have been implicated in the pathogenesis of lymphocytic alveolitis. 31 In our experience the development of NILC has no negative impact on survival after BMT in contrast to infectious interstitial pneumonitis. We observed a 90% response rate to immunosuppressive therapy in our patients, while 20% of these showed a relapsing/remitting pattern of response similar to other immune-mediated diseases. Schwarer et al 13 have described a similar response rate whereas treatment outcome was less favourable in the other published series.
14,17 These differences may be related to the varying proportion of patients with bronchiolitis obliterans contained in these patient series, because this entity usually exhibits a poor to moderate response to immunosuppressive therapy. [7] [8] [9] The main cause of treatment failure was infection as in patients with other manifestations of chronic GVHD.
In summary, patients with late onset pulmonary problems after allogeneic stem cell transplants and donor lymphocyte infusions should be carefully evaluated for the presence of an infectious agent. If no infectious cause can be identified, patients should be subjected to a course of steroid therapy on the assumption that they are suffering from a manifestation of chronic GVHD. The outcome of these patients is expected to be favorable.
